Review: Current knowledge on the role of HPV antibodies after natural infection and vaccination: Implications for monitoring an HPV vaccination programme

Journal of Medical Virology

Volumn 85, Issue 8, 2013, Pages 1379-1385

  Mollers, Madelief ^a,b   Vossen, Jeanique M ^a,b   Scherpenisse, Mirte ^a,b   van der Klis, Fiona R M ^a   Meijer, Chris J L M ^b   de Melker, Hester E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Human papillomavirus; Reinfection; Serology; Serosurveillance

Indexed keywords

IMMUNOSUPPRESSIVE AGENT; WART VIRUS VACCINE;

ANTIBODY RESPONSE; DNA VIRUS INFECTION; HIGH RISK BEHAVIOR; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; REVIEW; SEXUAL BEHAVIOR; VACCINATION; VIRUS LOAD; WART VIRUS;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; EPIDEMIOLOGICAL MONITORING; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION;

HUMAN PAPILLOMAVIRUS;

EID: 84879151548     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23616     Document Type: Review

References (69)

1. Baseman JG, Koutsky LA. 2005. The epidemiology of human papillomavirus infections. J Clin Virol 32:S16-S24.
2. Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen TE, Fortenberry JD. 2005. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis 191:182-192.
3. Bruni L, Diaz M, Castellsagué X, Ferrer E, Bosch FX, de Sanjosé S. 2010. Cervical human papillomavirus prevalence in 5 continents: Meta-analysis of 1 million women with normal cytological findings. J Infect Dis 202:1789-1799.
4. Carter JJ, Koutsky LA, Wipf GC, Christensen ND, Lee SK, Kuypers J, Kiviat N, Galloway DA. 1996. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J Infect Dis 174:927-936.
5. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N, Galloway DA. 2000. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181:1911-1919.
6. Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, Bryan J, Vuocolo S, Haupt RM, Saah A. 2011. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 105:28-37.
7. Clifford GM, Shin H-R, Oh J-K, Waterboer T, Ju Y-H, Vaccarella S, Quint W, Pawlita M, Franceschi S. 2007. Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea. Cancer Epidemiol Biomarkers Prev 16:1874-1879.
8. David M, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. 2009. Long-term persistence of anti-hpv-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: Modeling of sustained antibody responses. Gynecol Oncol 15:S1-S6.
9. de Gruijl TD, Bontkes HJ, Walboomers JM, Schiller JT, Stukart MJ, Groot BS, Chabaud MM, Remmink aJ, Verheijen RH, Helmerhorst TJ, Meijer CJ, Scheper RJ. 1997. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J Natl Cancer Inst 89:630-638.
10. de Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. 2007. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 7:453-459.
11. Dessy F, Giannini S, Bougelet C, Kemp T, David M, Poncelet S, Pinto L, Wettendorff M. 2008. Correlation between direct Elisa, single epitope-based inhibition elisa and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. HumVaccin 4:425-434.
12. Dias D, Doren JV, Schlottmann S, Puchalski D, Ruiz W, Boerckel P, Kessler J, Antonello JM, Green T, Smith J, Chirmule N, Barr E, Jansen KU, Esser MT, Kelly S, Brown M. 2005. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human. Clin Diagn Lab Immunol 12:959-969.
13. Dillner J, Arbyn M, Dillner L. 2007. Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination. Clin Exp Immunol 148:199-207.
14. Doorbar J. 2005. The papillomavirus life cycle. J Clin Virol 32:S7-S15.
15. Einstein M, Baron M, Levin M, Chatterjee A, Fox B, Scholar S, Rosen J, Chakhtoura N, Lebacq M, van der Most R, Moris P, Giannini S, Schuind A, Datta S, Descamps D, Group H-S. 2011. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 7:1359-1373.
16. Evans AS. 1980. The need for serologic evaluation of immunization programs. Am J Epidemiol 112:725-731.
17. Fedova D, Bruckova M, Plesnik V, Slonim D, Sejda J, Svandova E, Kubinova I. 1987. Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test. J Hyg Epidemiol Microbiol Immunol 31:409-422.
18. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA. 2007. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 356:1928-1943.
19. Gravitt PE. 2011. The known unknowns of HPV natural history. J Clin Invest 121:4593-4599.
20. Gruijl TDD, Bontkes HJ, Walboomers JMM, Coursaget P, Stukart MJ, Dupuy C, Kueter E, Verheijen RHM, Helmerhorst TJM, Duggan-keen MF, Stern PL, Meijer CJLM, Scheper RJ. 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia-I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome. J Gen Virol 80:399-408.
21. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G. 2004. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomised controlled trial. Lancet 364:1757-1765.
22. Haupt RM, Wheeler CM, Brown DR, Garland SM, Ferris DG, Paavonen JA, Lehtinen MO, Steben M, Joura Ea, Giacoletti KED, Radley DR, James MK, Saah AJ, Sings HL. 2011. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer 129:2632-2642.
23. Herfs M, Yamamoto Y, Laury A, Wang X, Nucci MR, McLaughlin-Drubin ME, Munger K, Feldman S, McKeon FD, Xian W, Crum CP. 2012. A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancer. Proc Natl Acad Sci USA 109:10516-10521.
24. Herrero R, Hildesheim a, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M. 2000. Population-based study of human papillomavirus infection and cervical neoplasia in Rural Costa Rica. J Natl Cancer Inst 92:464-474.
25. Hildesheim A, Herrero R, Wacholder S, Rodriguez AC, Solomon D, Bratti MC, Schiller JT, Gonzalez P, Dubin G, Porras C, Jimenez SE, Lowy DR. 2007. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 298:743-753.
26. Hillman RJ, Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Vardas E, Aranda C, Jessen H, Ferris DG, Coutlee F, Marshall JB, Vuocolo S, Haupt RM, Guris D, Garner EIO. 2012. Immunogenicity of the quadrivalent human papillomavirus (Type 6/11/16/18) vaccine in males 16 to 26 years old. CVI 19:261-267.
27. Ho G, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423-428.
28. Ho GYF, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, Burk RD. 2002. Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles. J Infect Dis 186:737-742.
29. Ho GYF, Studentsov YY, Bierman R, Burk RD. 2004. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol Biomarkers Prev 13:110-116.
30. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM. 2012. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: Retrospective pooled analysis of trial data. BMJ 344:e1401.
31. Kirnbauer R, Hubbert NL, Wheeler CM, Becker TM, Lowy DR, Schiller JT. 1994. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J Natl Cancer Inst 66:494-499.
32. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, Skinner SR, Apter D, Naud P, Salmerón J, Chow S-N, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, De Carvalho NS, Germar MJV, Peters K, Mindel A, De Sutter P, Bosch FX, David M-P, Descamps D, Struyf F, Dubin G. 2012. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-Year end-of-study analysis of the randomised, double-blind patricia trial. Lancet Oncol 13:89-99.
33. Lu B, Hagensee ME, Lee J-H, Wu Y, Stockwell HG, Nielson CM, Abrahamsen M, Papenfuss M, Harris RB, Giuliano AR. 2010. Epidemiologic factors associated with seropositivity to human papillomavirus type 16 and 18 virus-like particles and risk of subsequent infection in men. Cancer Epidemiol Biomarkers Prev 19:511-516.
34. Malik ZA, Hailpern SM, Burk RD. 2009. Persistent antibodies to HPV virus-like particles following natural infection are protective against subsequent cervicovaginal infection with related and unrelated HPV. Viral Immunol 22:445-449.
35. Mark, ?? Baron M, Levin MJ, Zepp F, Dessy FJ, Trofa F, Dubin G, Group H. 2009. Comparison of the immunogenicity and safety of cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 5:705-719.
36. Moscicki AB, Shiboski S, Broering J, Powell K, Clayton L, Jay N, Darragh TM, Brescia R, Kanowitz S, Miller SB, Stone J, Hanson E, Palefsky J. 1998. The natural history of human papillomavirus infection as measured by repeated DNA testing in adolescent and young women. J Pediatr 132:277-284.
37. Nonnenmacher B, Pintos J, Bozzetti MC, Mielzinska-Lohnas I, Lorincz AT, Ikuta N, Schwartsmann G, Villa LL, Schiller JT, Franco E. 2003. Epidemiologic correlates of antibody response to human papillomavirus among women at low risk of cervical cancer. Int J STD AIDS 14:258-265.
38. Olsson S-E, Villa LL, Costa RLR, Petta Ca, Andrade RP, Malm C, Iversen O-E, Høye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, von Krogh G, Lehtinen M, Paavonen J, Tamms GM, Giacoletti K, Lupinacci L, Esser MT, Vuocolo SC, Saah AJ, Barr E. 2007. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 Virus-Like Particle (Vlp) Vaccine. Vaccine 25:4931-4939.
39. Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski a, Romanowski B, Aoki FY, Schwarz TF, Poppe WAJ, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. 2009. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (Patricia): Final analysis of a double-blind, randomised study in young women. Lancet 374:301-314.
40. Pastrana DV, Buck CB, Pang Y-YS, Thompson CD, Castle PE, FitzGerald PC, Krüger Kjaer S, Lowy DR, Schiller JT. 2004. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321:205-216.
41. Petäjä T, Pedersen C, Poder A, Strauss G, Catteau G, Thomas F, Lehtinen M, Descamps D. 2011. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 129:2147-2157.
42. Petter A, Heim K, Guger M, Ciresa-Kö Nig A, Christensen N, Sarcletti M, Wieland U, Pfister H, Zangerle R, Höpfl R. 2000. Specific serum IgG, IgM and IgA antibodies to human papillomavirus types 6, 11 16, 18 and 31 virus-like particles in human immunodeficiency virus-seropositive women. J Gen Virol 81:701-708.
43. Porras C, Bennett C, Safaeian M, Coseo S, Rodríguez AC, González P, Hutchinson M, Jiménez S, Sherman ME, Wacholder S, Solomon D, van Doorn L-J, Bougelet C, Quint W, Schiffman M, Herrero R, Hildesheim A. 2010. Determinants of seropositivity among HPV-16/18 DNA positive young women. BMC Infect Dis 10:238-238.
44. Rodríguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, Solomon D, Burk R. 2008. Rapid clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl Cancer Inst 100:513-517.
45. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D. 2012. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up. Hum Vaccin Immunother 8:390-397.
46. Safaeian M, Porras C, Schiffman M, Rodriguez AC, Wacholder S, Gonzalez P, Quint W, van Doorn L-J, Sherman ME, Xhenseval V, Herrero R, Hildesheim A. 2010. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 102:1653-1662.
47. Scherpenisse M, Mollers M, Schepp RM, Boot HJ, Meijer CJ, Berbers GA, van der Klis FR, de Melker HE. 2012. Changes in antibody seroprevalence of seven high-risk HPV types between nationwide surveillance studies from 1995-96 and 2006-07 in the Netherlands. PLoS ONE 7:e48807.
48. Silverberg MJ, Schneider MF, Silver B, Anastos KM, Burk RD, Minkoff H, Levine AM, Viscidi RP, Palefsky J. 2006. Serological detection of human papillomavirus type 16 infection in human immunodeficiency virus (HIV)-positive and high-risk HIV-negative women. Clin Vaccine Immunol 2006 13:511-519.
49. Stanley M. 2006. Immune responses to human papillomavirus. Vaccine 24:S16-S22.
50. Stanley M. 2010. HPV: Immune response to infection and vaccination. Infect Agent Cancer 20:5.
51. Sycuro LK, Xi LF, Hughes JP, Feng Q, Winer RL, Lee S-K, O'Reilly S, Kiviat NB, Koutsky LA. 2008. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 198:971-978.
52. Szarewski A, Poppe WA, Skinner SR, Wheeler CM, Paavonen J, Naud P, Salmeron J, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Hedrick J, Jaisamrarn U, Limson G, Garland S, Romanowski B, Aoki FY, Schwarz TF, Bosch FX, Harper DM, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G. 2011. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15-25 years with and without serological evidence of previous exposure to HPV-16/18. 2012. Int J Cancer 131:106-116.
53. Touzé A, de Sanjose S, Coursaget P, Rosa Almirall M, Palacio V, Meijer CJLM, Kornegay J, Xavier Bosch F. 2001. Prevalence of anti-human papillomavirus type 16, 18 31, and 58 virus-like particles in women in the general population and in prostitutes. J Clin Microbiol 39:4344-4348.
54. Trottier H, Ferreira S, Thomann P, Costa MC, Sobrinho JS, Prado JCM, Rohan TE, Villa LL, Franco EL. 2010. Human papillomavirus infection and reinfection in adult women: The role of sexual activity and natural immunity. Cancer Res 70:8569-8577.
55. Vaccarella S, Franceschi S, Clifford GM, Touzé A, Hsu CC, de Sanjosé S, Pham THA, Nguyen TH, Matos E, Shin HR, Sukvirach S, Thomas JO, Boursaghin L, Gaitan J, Snijders PJF, Meijer CJLM, Muñoz N, Herrero R, Coursaget P. 2010. Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: The international agency for research on cancer HPV prevalence surveys. Cancer Epidemiol Biomarkers Prev 19:2379-2388.
56. van Lier EA, Giesbers H, Drijfhout IH, de Hoogh PAAM, de Melker HE. 2012. Vaccinatiegraad Rijksvaccinatieprogramma Nederland: Verslagjaar 2012. Rivm Rapport Nr. 201001001. Bilthoven: Rijksinstituut Voor Volksgezondheid En Milieu, 2012.
57. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson S-E, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E. 2005. Prophylactic quadrivalent human papillomavirus (types 6, 11 16, and 18) L1 virus-like particle vaccine in young women: A randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:271-278.
58. Viscidi RP. 2004. Seroreactivity to human papillomavirus (hpv) types 16, 18 or 31 and risk of subsequent HPV infection: Results from a population- based study in Costa Rica. Cancer Epidemiol Biomarkers Prev 13:324-327.
59. Viscidi RP, Kotloff KL, Clayman B, Russ K, Shapiro S, Shah KV. 1997. Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol 4:122-126.
60. Viscidi RP, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, Sobel J, Shah KV. 2005. Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev 14:283-283.
61. Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim a, Rodriguez aC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Clayman B, Burk RD, Viscidi RP. 2004. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10, 000 women in Costa Rica. Br J Cancer 91:1269-1274.
62. Ward BJ, Boulianne N, Ratnam S, Guiot MC, Couillard M, De Serres G. 1995. Cellular immunity in measles vaccine failure: Demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after revaccination. J Infect Dis 172:1591-1595.
63. Waterboer T, Sehr P, Michael KM, Franceschi S, Nieland JD, Joos TO, Templin MF, Pawlita M. 2005. Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins. Clin Chem 51:1845-1853.
64. Weaver B, Shew M, Qadadri B, Tu W, Tong Y, Denski C, Fortenberry JD, Ermel A, Brown D. 2011. Low-level persistence of human papillomavirus 16 DNA in a cohort of closely followed adolescent women. J Med Virol 83:1362-1369.
65. Weibel RE, Buynak EB, McLean AA, Hilleman MR. 1975. Long-term follow-up for immunity after monovalent or combined live measles, mumps, and rubella virus vaccines. Pediatrics 56:380-387.
66. Wideroff L, Schiffman MH, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lowy D, Lorincz AT, Manos MM, Glass AG. 1995. Evaluation of seroreactivity to human papillomavirus type 16 virus-like particles in an incident case-control study of cervical neoplasia. J Infect Dis 172:1425-1430.
67. Wideroff L, Schiffman MH, Hoover R, Tarone RE, Nonnenmacher B, Hubbert N, Kirnbauer R, Greer CE, Lorincz AT, Manos MM, Glass AG, Scott DR, Sherman ME, Buckland J, Lowy D, Schiller J. 1996. Epidemiologic determinants of seroreactivity to human papillomavirus (HPV) type 16 virus-like particles in cervical HPV-16 DNA-positive and-negative women. J Infect Dis 174:937-943.
68. Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O'Reilly S, Kiviat NB, Koutsky LA. 2011. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev 20:699-707.
69. zur Hausen H, Gissmann L, Steiner W, Dippold W, Dreger J. 1975. Human papilloma viruses and cancer. Bibl Haematol 43:569-571.